Loss of p53 impairs death receptor expression and confers resistance to CD19 CAR T-cell therapy in BCP-ALL

Abstract: Loss of p53 function predicts a dismal outcome in relapsed B-cell precursor acute lymphoblastic leukemia (BCP-ALL). Chimeric antigen receptor T-cell (CAR T) therapy was recently approved to salvage relapsed/refractory BCP-ALL. We observed a significantly worse overall survival after CD19-t...

Full description

Bibliographic Details

Published in:	Blood Neoplasia
Main Authors:	Willem P. J. Cox, Noël M. M. Dautzenberg, Linde Dekker, Tesa Klenovsek, Annelisa M. Cornel, Marliek van Hoesel, Dorette S. van Ingen Schenau, Reno S. Bladergroen, Roland P. Kuiper, Laurens T. van der Meer, Friso G. Calkoen, Stefan Nierkens, Frank N. van Leeuwen
Format:	Article
Language:	English
Published:	Elsevier 2025-02-01
Online Access:	http://www.sciencedirect.com/science/article/pii/S2950328024000608